AmpliPhi acquires key bacteriophage assets from UK-based Novolytics
Acquired assets will broaden AmpliPhi’s IP portfolio and speed the development of phage therapies
AmpliPhi Biosciences, a developer of bacteriophage-based antibacterial therapies to treat drug-resistant infections, has acquired key assets from UK-based Novolytics, including bacteriophage-related intellectual property, bacteriophage libraries, formulation and regulatory know-how as well as GLP toxicology data.
M. Scott Salka, CEO of AmpliPhi Biosciences, said: ‘These Novolytics assets will broaden our IP portfolio and speed the development of our phage therapies. This acquisition supports our strategy of assembling the premier bacteriophage therapy company through the acquisition of world-class talent and assets to accomplish our goal of arming physicians and patients with novel and effective weapons against the growing threat of antibiotic-resistant pathogens.’
Previous AmpliPhi acquisitions include Biocontrol of London, UK, acquired in late 2010, and Special Phage Services (Sydney, Australia), acquired in late 2012. AmpliPhi maintains a research and development facility in Sydney and, as a direct result of earlier relationships forged by Special Phage Services with Flinders and Adelaide Universities in South Australia, expects to soon be dosing chronic rhinosinusitis patients in its first clinical trial of a phage therapeutic at the Queen Elizabeth Hospital in Adelaide.
